首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   32742篇
  免费   6045篇
  国内免费   102篇
耳鼻咽喉   167篇
儿科学   729篇
妇产科学   1948篇
基础医学   1925篇
口腔科学   452篇
临床医学   16634篇
内科学   5216篇
皮肤病学   288篇
神经病学   1979篇
特种医学   734篇
外科学   3033篇
综合类   326篇
一般理论   11篇
预防医学   2684篇
眼科学   319篇
药学   966篇
中国医学   10篇
肿瘤学   1468篇
  2023年   827篇
  2022年   158篇
  2021年   465篇
  2020年   735篇
  2019年   399篇
  2018年   1342篇
  2017年   1496篇
  2016年   1580篇
  2015年   1679篇
  2014年   1841篇
  2013年   2465篇
  2012年   1243篇
  2011年   1620篇
  2010年   1539篇
  2009年   1772篇
  2008年   1493篇
  2007年   1465篇
  2006年   1483篇
  2005年   1355篇
  2004年   1203篇
  2003年   1148篇
  2002年   1077篇
  2001年   636篇
  2000年   419篇
  1999年   585篇
  1998年   750篇
  1997年   824篇
  1996年   763篇
  1995年   690篇
  1994年   524篇
  1993年   444篇
  1992年   398篇
  1991年   363篇
  1990年   329篇
  1989年   296篇
  1988年   262篇
  1987年   231篇
  1986年   241篇
  1985年   277篇
  1984年   262篇
  1983年   237篇
  1982年   211篇
  1981年   205篇
  1980年   176篇
  1979年   141篇
  1978年   125篇
  1977年   131篇
  1976年   140篇
  1974年   97篇
  1972年   125篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is imperfect with one-third of low-risk patients developing disease resistance to first-line single-agent chemotherapy. We aimed to generate simplified models that improve upon FIGO. Logistic regression (LR) and multilayer perceptron (MLP) modelling (n = 4191) generated six models (M1-6). M1, all eight FIGO variables (scored data); M2, all eight FIGO variables (scored and raw data); M3, nonimaging variables (scored data); M4, nonimaging variables (scored and raw data); M5, imaging variables (scored data); and M6, pretreatment hCG (raw data) + imaging variables (scored data). Performance was compared to FIGO using true and false positive rates, positive and negative predictive values, diagnostic odds ratio, receiver operating characteristic (ROC) curves, Bland-Altman calibration plots, decision curve analysis and contingency tables. M1-6 were calibrated and outperformed FIGO on true positive rate and positive predictive value. Using LR and MLP, M1, M2 and M4 generated small improvements to the ROC curve and decision curve analysis. M3, M5 and M6 matched FIGO or performed less well. Compared to FIGO, most (excluding LR M4 and MLP M5) had significant discordance in patient classification (McNemar's test P < .05); 55-112 undertreated, 46-206 overtreated. Statistical modelling yielded only small gains over FIGO performance, arising through recategorisation of treatment-resistant patients, with a significant proportion of under/overtreatment as the available data have been used a priori to allocate primary chemotherapy. Streamlining FIGO should now be the focus.  相似文献   
2.
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs.  相似文献   
3.
4.
5.
6.
7.
8.
9.
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号